LSTA Tingkat bathi reged Lisata Therapeutics

LSTA (Lisata Therapeutics) - tandha merek perusahaan

Gross margin dynamics correlate with clinical trials of tumor permeability agents amid stable cash reserves for Lisata Therapeutics (LSTA). Revenues are based on the commercialization of LSTA1 for pancreatic treatment, although a fierce patent race with pharma behemoths creates risks. The 76.00 metric reflects current dynamics, capturing the balance of market forces and stripping the historical trend of random price anomalies.

Lisata Therapeutics (LSTA): Rentabilitas reged saka 28.04.2023 nganti 20.11.2026

Rincian metrik keuangan lan pasar Lisata Therapeutics (LSTA)

- nilai saham lan prakiraan konsensus rega:
Analisis dhasar perusahaan:LSTA - Lisata Therapeutics
Produk dadi Lisata

Fundamental screening of the LSTA asset requires an analysis of direct cost management efficiency by monitoring production profitability. The gross margin history reflects the profit share after deducting the cost of goods sold, which is critical for Lisata Therapeutics as it scales partnerships with oncology clinics to implement tumor permeability technologies for pancreatic cancer therapy.